Ovagen 20mg (Bioregulator)

Amino Acid Sequence: Glu-Asp-Leu (EDL)
Molecular Formula: C₁₅H₂₅N₃O₈
Molecular Weight: 375.37 g/mol
PubChem CID: 444128
Synonyms: EDL, glutamyl-aspartyl-leucine, SCHEMBL5329396, 1a30, CHEBI:137252

Source: PubChem

Ovagen is supplied exclusively for laboratory research use. Reported research applications include in-vitro and in-vivo experimental designs examining peptide-mediated regulation of hepatic and gastrointestinal cellular systems. Typical use cases include: (i) studies of transcriptional regulation and chromatin accessibility in liver-derived cells; (ii) evaluation of extracellular matrix and fibrotic-marker expression in animal models; (iii) gastrointestinal epithelial barrier and mucosal signaling assays; and (iv) enzymatic interaction studies in virological or biochemical assay systems where peptide–enzyme binding is investigated under controlled conditions.

Mechanistic descriptions of Ovagen in the literature emphasize its classification as a short peptide capable of interacting with intracellular regulatory systems. Experimental findings are commonly framed around modulation of chromatin structure, transcription-factor accessibility, and downstream gene-expression patterns in tissue-specific models. In hepatic and gastrointestinal systems, these mechanisms are evaluated through changes in markers associated with cellular proliferation, extracellular matrix organization, and mucosal signaling pathways within defined experimental time courses.

Separate biochemical studies describe Ovagen as a low–molecular weight peptide capable of interacting with viral protease enzymes in vitro. In this context, enzymatic inhibition is assessed using purified enzyme systems and substrate-cleavage assays, providing mechanistic insight into peptide–protease binding and inhibition dynamics without implication of clinical or translational application.

Preclinical investigations cited for Ovagen include in-vitro biochemical assays and animal-based experimental models. In hepatic systems, studies examine peptide-associated changes in fibrotic markers, cellular proliferation indices, and transcriptional activity under experimentally induced stress or injury paradigms. Gastrointestinal research focuses on epithelial and mucosal signaling readouts relevant to barrier integrity and cellular turnover within controlled animal models.

Additional biochemical research evaluates Ovagen in enzyme-inhibition assays involving viral proteases. These studies are conducted using isolated enzymes and synthetic substrates, with outcomes reported as concentration-dependent effects on enzymatic activity. All findings are presented within the scope of exploratory, non-clinical laboratory research.

This product is provided strictly as a research reagent. Standard analytical characterization for short peptides may include chromatographic purity analysis (e.g., HPLC or UPLC) and molecular mass confirmation by mass spectrometry. Lot-specific certificates of analysis (COA) should be consulted for identity and purity data relevant to experimental documentation and quality control.